HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION

Lobbying for HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$30,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Virginia

Official filing document

Lobbyists on this filing 3

WYETH RUTHVEN

Previously held: Press Secretary, Rep. Lloyd Doggett, 2006-2009; Staff Assistant, Sen. Fritz Hollings, 1996-1999
MAGGIE DAVIS New on this filing

Previously held: Legal Fellow, Rep. Jan Schakowsky, 2012.
KATHRYN DIBITETTO

Previously held: Senior Legislative Assistant, Rep. Mike McMahon, 2009-2011

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 11

Commerce, Dept of (DOC)
Environmental Protection Agency (EPA)
Federal Emergency Management Agency (FEMA)
Federal Maritime Commission
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE
Transportation, Dept of (DOT)
U.S. Trade Representative (USTR)
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

S 998
Medical Supply Chain Resiliency Act
HR 2213
Medical Supply Chain Resiliency Act
S 891
Bipartisan Health Care Act
S 257
Promoting Resilient Supply Chains Act of 2025

Lobbying activity 3

Health Issues

Medical Supply Chain Resiliency Act (S. 998/HR 2213). Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) either as standalone legislation or inclusion in a larger package such as S.891, the Bipartisan Health Care Act.

Transportation

S.257, the Promoting Resilient Supply Chains Act of 2025.

Tariff (miscellaneous tariff bills)

Legislative and executive branch action with respect to tariffs and tariff exclusions on medical products: including IEEPA reciprocal tariffs, IEEPA border/fentanyl tariffs on China, Mexico and Canada, tariff investigations pursuant to Sec 301 and Sec 232 on medical products. Medical Supply Chain Resiliency Act (S. 998/HR 2213)

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.